Skip to main content
Equibles

Affinity Asset Advisors, LLC

Position in NXTC — NextCure, Inc.

CIK 1773195 NEW YORK, NY
Back to NXTC Full portfolio

Position in NXTC

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$67,136
-$2,515,565 QoQ
Shares Held
41,960
-82.6% QoQ
Ownership
0.917%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#11
of 30 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NXTC Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Affinity Asset Advisors, LLC holds $1,842,784,374 across 87 Biotechnology names. NXTC ranks #85 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ROIV
Roivant Sciences Ltd.
 3,750,000 $132,712,500
2 APGE
Apogee Therapeutics, Inc.
 987,000 $131,004,510
3 SYRE
Spyre Therapeutics, Inc.
 1,279,134 $113,561,516
4 XENE
Xenon Pharmaceuticals Inc.
 1,595,000 $96,274,200
5 ERAS
Erasca, Inc.
 5,250,000 $96,180,000
6 INSM
INSMED Inc
 650,000 $69,303,000
7 PRAX
Praxis Precision Medicines, Inc.
 185,000 $61,936,150
8 ORKA
Oruka Therapeutics, Inc.
 590,000 $56,150,300

All Filings in NXTC

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $67,136 41,960
2026-03-31 $2,582,701 241,826
2025-12-31 $3,509,101 247,294
2025-09-30 $1,124,428 191,882
2025-06-30 $1,059,195 2,302,598
2025-03-31 $1,105,247 2,302,598
2024-12-31 $1,775,303 2,302,598
2024-09-30 $3,154,559 2,302,598
2024-06-30 $2,683,848 1,687,955
2024-03-31 $3,030,652 1,359,037